Sort
48,018 grants matching “immunotherapy”
Immunotherapy to prevent oral permalignant lesion recurrence and oral cancer.
$361,449M. Rita Young · Medical University Of South Carolina · R01 · FY2010 · CA
Project 3: Chronic interferon and bile acid signaling as drivers of immunosuppression in age-related liver cancer
$361,441Susan M Kaech · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2025 · AG
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapy
$361,440Gen-Sheng Feng · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2025 · AG
Target MIC shedding to revive anti-tumor immunity
$361,425Jennifer D Wu · Northwestern University At Chicago · R01 · FY2020 · CA
Therapeutic targeting of demethylation-deubiquitination axis in acute leukemia
$361,425Panagiotis Ntziachristos · Northwestern University At Chicago · R01 · FY2020 · CA
Uveitogenic Epitope(s) and Idiopathic Anterior Uveitis
$361,375Nalini S. Bora · Univ Of Arkansas For Med Scis · R01 · FY2014 · EY
Uveitogenic Epitope(s) and Idiopathic Anterior Uveitis
$361,375Nalini S. Bora · Univ Of Arkansas For Med Scis · R01 · FY2015 · EY
New Strategies for Treatment of NRAS Mutant Melanoma after Progression on Immune Checkpoint Inhibitors
$361,357Ann Richmond · Vanderbilt University · R01 · FY2024 · CA
Image-guided Interventional Combination Liver Cancer Immunotherapy
$361,348Zhuoli Zhang · University Of California-Irvine · R01 · FY2022 · CA
Image-guided Interventional Combination Liver Cancer Immunotherapy
$361,328Zhuoli Zhang · University Of California-Irvine · R01 · FY2023 · CA
Artif. Antigen Presentation to Sensitize Virus-Spec. TCells for Adoptive Immunoth
$361,319Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2007 · CA
Mechanisms and Therapy of Bacterial Keratitis
$361,305Richard Joseph O'Callaghan · University Of Mississippi Med Ctr · R01 · FY2006 · EY
Intracerebrally delivered EGFRvIII-targeted CARs for brain tumors
$361,290John H Sampson · Duke University · P50 · FY2017 · CA
Amelioration of recurrent herpes keratitis
$361,247Washington University · R01 · FY2004 · EY
OVERCOMING LOCAL AND PERIPHERAL IMMUNE SUPPRESSION IN GLIOMA TO FACILITATE EFFEC
$361,125Andrew T Parsa · University Of California, San Francisco · P50 · FY2017 · CA
P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy
$361,117Yong Lu · Methodist Hospital Research Institute · R37 · FY2023 · CA
Induction of Anti-Tumor Immunity after HC Transplant
$361,114Robert Jon Soiffer · Dana-Farber Cancer Inst · U19 · FY2006 · AI
Targeting exploitable vulnerabilities in T-cell Lymphoma
$361,108Samuel Ng · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Antibody Gene Therapy for Methamphetamine Abuse
$361,091Eric C Peterson · Univ Of Arkansas For Med Scis · R01 · FY2015 · DA
Regulation of PD-L1/PD-1 immune checkpoints by cis-interactions
$361,044Enfu Hui · University Of California, San Diego · R37 · FY2021 · CA
Core 3: Biostatistics and Bioinformatics Core
$361,019Ted Gooley · University Of Washington · P01 · FY2021 · CA
Antibody-Targeted Cancer Immunotherapy
$361,011Louis M Weiner · Georgetown University · R01 · FY2014 · CA
TARGETING PCD FOR CANCER THERAPY
$361,000University Of Michigan At Ann Arbor · P01 · FY2003 · CA
Mutant BRAF as a Therapeutic Target for Melanoma
$360,960Dorothee M Herlyn · Wistar Institute · P01 · FY2011 · CA
Regulation of antigen presenting cells in the tumor microenvironment by retinoic acid
$360,922Malay Haldar · University Of Pennsylvania · R37 · FY2023 · CA